The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study.
 
Peijian Peng
No Relationships to Disclose
 
Xiaolu Xu
No Relationships to Disclose
 
Jincai Zhong
No Relationships to Disclose
 
Jin-Hui Ye
No Relationships to Disclose
 
Zhi-Hui Wang
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
Hong Lin
No Relationships to Disclose
 
Caiwen Du
No Relationships to Disclose
 
Guorong Zou
No Relationships to Disclose
 
Jie Ouyang
No Relationships to Disclose
 
Ying-ying Shi
No Relationships to Disclose
 
Fei Xu
No Relationships to Disclose
 
Gengsheng Yu
No Relationships to Disclose
 
Yongkui Lu
No Relationships to Disclose
 
Yong-Xia Wang
No Relationships to Disclose
 
Shi-En Cui
No Relationships to Disclose
 
Lu-Zhen Li
No Relationships to Disclose